Schrödinger is discontinuing the development of its blood cancer CDC7 inhibitor after two patient deaths. In a Phase I trial ...

AbbVie Inc.’s stock rose 7.7% Friday to lead S&P 500 gainers after the drug company beat fourth-quarter earnings estimates and offered an upbeat view of 2025, as its newer immunology drugs ...

From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.

During a live event, Andrew H. Lipsky, MD, and participants debate BTK plus BCL2 inhibitor benefits, barriers, and optimal ...

Thousands of Medicare recipients will face higher costs for expensive cancer drugs following passage of two provisions in the One Big Beautiful Bill Act, signed by President Donald Trump in July, The ...

July marks a transformative month in oncology with the FDA's groundbreaking approvals and updates, enhancing treatment ...

While the stock market has been on a strong winning streak recently, you should only be putting cash into stocks that you want to hold for at least three to five years. Dividend stocks can be a great ...

AbbVie has delivered robust financial performance of late, with notable revenue growth from its immunology portfolio. That growth has been driven by longtime blockbusters like Skyrizi and Rinvoq.

Q2 2025 Earnings Call Transcript July 31, 2025 AbbVie Inc. beats earnings expectations. Reported EPS is $2.97, expectations were $2.88. Operator: Good morning, and thank you for standing by. Welcome ...

AbbVie Inc (ABBV) surpasses expectations with robust sales from Skyrizi and Rinvoq, while navigating Humira declines and ...

On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion. Sales increased 6.6% on a reported basis or 6.5% on ...

Discover AbbVie's standout Q2 2025 earnings insights, with strong Skyrizi & Rinvoq growth, raised revenue guidance, and robust R&D progress driving ...